Early bird registration is open and closes May 2025. Register now
Synopsis: The purpose of this symposium is to outline the paradigm shift in understanding the pathophysiology and new treatments strategy in SLE/Lupus. Agenda: Chairperson: Prof.
Agenda: Chairperson: Prof Yuko Kaneko 18:15 Welcome Remarks: Introduction 18:20-18:45 The utility of the collaboration of ultrasound examination and early biologics therapy for PsA ~Achilles’s
Ozoralizumab as a Novel Therapeutic Option for Rheumatoid Arthritis in a Super-Aged Society
Agenda: Chairperson: Dr. Kunihiro Yamaoka TBA mins Welcome Remarks: Introduction TBA mins Frontiers in targeted therapy on RANKL: Bone protection strategy for rheumatic diseases by
Agenda: Chairperson/s: Prof. Hoon-Suk Cha and Prof. Kunihiro Yamaoka 13:40-13:50 Welcome Remarks: Introduction 13:50-14:10 Etanercept: A pillar of RA Therapy with Proven Safety and Long-term
Agenda: Chairperson: Roger Levy TBA mins Introduction – SLE/LN in Asia : our current challenges Prof. Yoshiya Tanaka TBA mins Avoiding progression in SLE –
Synopsis: It is 15 years since the first Treat-to-Target recommendations in rheumatoid arthritis (RA) were published. In 2025, this treatment strategy for the management of
Synopsis: Treatment of rheumatoid arthritis has dramatically changed by the appearance of molecular target drugs, and the treatment option with JAK inhibitors had a large
Synopsis: Despite the implementation of the treat-to-target approach and recent advancements in biological therapy of rheumatoid arthritis there are still unmet needs that have to
Agenda: 08:30-08:31 Welcome Remarks: Introduction Chairperson: Prof. Yoshiya Tanaka 08:35-09:15 Adalimumab: A cornerstone in Rheumatology Prof. Josef Smolen
